Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Important Safety Information Do not use AOD-9604 if you: Have a known hypersensitivity to growth hormone fragments or any component of the formulation Have active malignancy (cancer that is currently being treated or monitored) Are pregnant or breastfeeding (insufficient safety data) Have a history of severe allergic reactions to peptide therapies Common side effects (typically mild and transient): Headache, mild gastrointestinal disturbances (flatulence, mild diarrhea at higher doses), upper respiratory tract symptoms, injection site reactions (redness, mild discomfort) Seek medical attention if you experience: Signs of allergic reaction (hives, difficulty breathing, swelling of face or throat), persistent gastrointestinal symptoms, unexplained significant changes in energy, mood, or physical symptoms Clinical Safety Data Safety studies involving approximately 900 participants across six randomized controlled trials documented that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo across most parameters
The discomfort typically presents as mild cramping or a sensation of fullness in the upper abdomen
Trust your instinctsif a side effect feels concerning or just wont go away, seeking medical advice is the most responsible course of action
For BPC-157 enthusiastsand they seem to be legionits welcome news
Since even a tiny math error can lead to serious issues, getting the numbers exactly right is vital
Full Staggered Titration Schedule Recommended staggered co-titration across 24 weeks Phase Reta initiation Weeks 1-4 Retatrutide 2 mg/week Cagrilintide Not started Notes Confirm retatrutide GI tolerance first
